Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMYT Amryt Pharma	$14.70 +0.1%	$14.64	$6.41 ▼ $14.77	$940.21M	0.84	757,360 shs	2.39 million shs
AURA Aura Biosciences	$6.80 +3.8%	$6.55	$4.34 ▼ $12.38	$329.26M	0.46	166,105 shs	148,610 shs
OGN Organon & Co.	$9.22 +1.2%	$9.77	$8.01 ▼ $23.10	$2.37B	0.6	4.53 million shs	5.25 million shs
SLN Silence Therapeutics	$5.04 -6.3%	$5.81	$1.97 ▼ $20.48	N/A	1.39	77,446 shs	69,069 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMYT Amryt Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
AURA Aura Biosciences	+3.82%	+0.89%	+3.19%	+30.02%	-16.97%
OGN Organon & Co.	+1.26%	-5.53%	-7.43%	+5.73%	-51.60%
SLN Silence Therapeutics	-6.32%	-18.31%	-22.22%	+36.22%	-70.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	1.9445 of 5 stars	3.6	0.0	0.0	0.0	2.1	3.3	0.0
OGN Organon & Co.	4.7949 of 5 stars	3.3	4.0	1.7	3.7	3.1	1.7	2.5
SLN Silence Therapeutics	2.1417 of 5 stars	3.4	3.0	0.0	0.0	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMYT Amryt Pharma	0.00	N/A	N/A	N/A
AURA Aura Biosciences	3.25	Buy	$22.00	223.53% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	95.23% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	571.30% Upside

Current Analyst Ratings Breakdown

Latest AURA, SLN, AMYT, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/13/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMYT Amryt Pharma	$222.54M	4.22	$0.98 per share	14.98	$5.58 per share	2.63
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
OGN Organon & Co.	$6.40B	0.37	$4.98 per share	1.85	$2.82 per share	3.27
SLN Silence Therapeutics	$43.26M	N/A	N/A	N/A	$4.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMYT Amryt Pharma	$1M	-$0.06	N/A	735.00	N/A	-8.19%	1.70%	0.75%	N/A
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
OGN Organon & Co.	$864M	$2.69	3.43	2.47	0.95	11.15%	163.88%	6.99%	N/A
SLN Silence Therapeutics	-$45.31M	-$1.50	N/A	N/A	N/A	-294.20%	-63.50%	-38.60%	8/21/2025 (Estimated)

Latest AURA, SLN, AMYT, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	SLN Silence Therapeutics	-$0.2067	N/A	N/A	N/A	$3.38 million	N/A
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	SLN Silence Therapeutics	-$0.27	-$0.54	-$0.27	-$0.57	$8.50 million	$0.22 million
8/5/2025	Q2 2025	OGN Organon & Co.	$0.94	$1.00	+$0.06	$0.56	$1.55 billion	$1.59 billion
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.87%	N/A	2.97%	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest AURA, SLN, AMYT, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	OGN Organon & Co.	quarterly	$0.02	0.9%	8/15/2025	8/15/2025	9/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMYT Amryt Pharma	0.64	1.57	0.94
AURA Aura Biosciences	N/A	11.06	11.06
OGN Organon & Co.	11.98	1.65	1.15
SLN Silence Therapeutics	N/A	8.81	8.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMYT Amryt Pharma	71.31%
AURA Aura Biosciences	96.75%
OGN Organon & Co.	77.43%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
AMYT Amryt Pharma	5.66%
AURA Aura Biosciences	5.40%
OGN Organon & Co.	1.96%
SLN Silence Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMYT Amryt Pharma	2,020	63.96 million	60.34 million	Not Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
OGN Organon & Co.	4,000	259.97 million	254.86 million	Not Optionable
SLN Silence Therapeutics	100	N/A	N/A	Not Optionable

AURA, SLN, AMYT, and OGN Headlines

Recent News About These Companies

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 7 at 8:02 AM | businesswire.com

Financial Review: Silence Therapeutics (NASDAQ:SLN) versus Gain Therapeutics (NASDAQ:GANX)

August 6 at 2:15 AM | americanbankingnews.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $33.83 Average PT from Analysts

August 1, 2025 | americanbankingnews.com

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

June 12, 2025 | businesswire.com

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

June 6, 2025 | zacks.com

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

May 21, 2025 | zacks.com

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8, 2025 | seekingalpha.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025 | businesswire.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.comB

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation

February 11, 2025 | msn.com

Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints

February 11, 2025 | seekingalpha.com

Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

February 11, 2025 | markets.businessinsider.com

Silence Therapeutics initiated with a Sell at Goldman Sachs

February 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
By MarketBeat Staff | July 29, 2025
View Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market

AURA, SLN, AMYT, and OGN Company Descriptions

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Aura Biosciences NASDAQ:AURA

$6.80 +0.25 (+3.82%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.81 +0.01 (+0.15%)

As of 08/8/2025 05:46 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Organon & Co. NYSE:OGN

$9.22 +0.11 (+1.21%)

Closing price 08/8/2025 03:59 PM Eastern

Extended Trading

$9.23 +0.01 (+0.11%)

As of 08/8/2025 07:56 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Silence Therapeutics NASDAQ:SLN

$5.04 -0.34 (-6.32%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.05 +0.01 (+0.18%)

As of 08/8/2025 07:11 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time